Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASEL | Q05823 | 9/20 | 0.84 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.82 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.81 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.81 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.81 |
| ▸ | LDHA | P00338 | 1/20 | 0.81 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.81 |
| ▸ | FBP1 | P09467 | 1/20 | 0.81 |
| ▸ | SRC | P12931 | 1/20 | 0.81 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.81 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.81 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.81 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.81 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.81 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.81 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.81 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.81 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.81 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30203821 | 1.00 | RNASEL (0.84) | RNASELADORA1DNPH1PRKAB2TRPM2 | |
| SCHEMBL1122523 | 1.00 | RNASEL (0.84) | RNASELADORA1DNPH1PRKAB2TRPM2 | |
| SCHEMBL21068029 | 1.00 | RNASEL (0.84) | RNASELADORA1DNPH1PRKAB2TRPM2 | |
| SCHEMBL31266503 | 0.93 | P2RY1 (0.83) | RNASELADORA1DNPH1PRKAB2TRPM2 | |
| SCHEMBL21067751 | 0.93 | P2RY1 (0.83) | RNASELADORA1DNPH1PRKAB2TRPM2 | |
| SCHEMBL23867092 | 0.93 | P2RY1 (0.83) | RNASELADORA1DNPH1PRKAB2TRPM2 | |
| SCHEMBL1061029 | 0.93 | P2RY1 (0.83) | RNASELADORA1DNPH1PRKAB2TRPM2 | |
| SCHEMBL15498428 | 0.93 | P2RY1 (0.83) | RNASELADORA1DNPH1PRKAB2TRPM2 | |
| SCHEMBL29431883 | 0.93 | P2RY1 (0.83) | RNASELADORA1DNPH1PRKAB2TRPM2 | |
| SCHEMBL42104 | 0.93 | P2RY1 (0.83) | RNASELADORA1DNPH1PRKAB2TRPM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11353448-B2 | Methods and compositions for quantifying metabolites and proteins from single cells | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2022-06-07 | — | — | US | claimed |
| US-20260034071-A1 | HIGH-PURITY PEG LIPIDS AND USES THEREOF | MODERNATX, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-12466874-B2 | Prevention of protein disulfide bond reduction | MEDIMMUNE LLC (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250320190-A1 | Novel Inhibitors of Leucine Carboxyl Methyltransferase-1 (LCMT-1) and Methods of Use Thereof | UNIV TEMPLE (US) | 2025-10-16 | — | — | US | disclosed |
| US-12383508-B2 | High-purity peg lipids and uses thereof | MODERNATX, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| CN-120060182-A | Nucleic acid modified protein and application thereof | 深圳市儿童医院 | 2025-05-30 | — | — | CN | disclosed |
| US-20250152518-A1 | PEG LIPIDS AND USES THEREOF | MODERNATX, INC. (US) | 2025-05-15 | — | — | US | disclosed |
| EP-4509118-A2 | HIGH-PURITY PEG LIPIDS AND USES THEREOF | ModernaTX, Inc. (US) | 2025-02-19 | — | — | EP | disclosed |
| CN-119355251-A | Identification mark for accurately distinguishing drinking death from post-death wine filling and identification method thereof | 山西医科大学 | 2025-01-24 | — | — | CN | disclosed |
| US-12151029-B2 | PEG lipids and uses thereof | MODERNATX, INC. (US) | 2024-11-26 | — | — | US | disclosed |
| CN-115605603-A | Method for producing sulfated polysaccharide and method for producing PAPS | 伦斯莱尔工艺研究院（US） | 2023-01-13 | — | — | CN | disclosed |
| US-20220265857-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | MODERNATX, INC. (US) | 2022-08-25 | — | — | US | disclosed |
| CN-113151316-B | Method for improving heat resistance of plants by controlling content of MECPP (mecPP) through controlling HDS22 gene | 湖北大学 | 2022-06-24 | — | — | CN | disclosed |
| CN-114616340-A | Process for the synthesis of anticoagulant polysaccharides | 奥普蒂姆维亚有限公司 | 2022-06-10 | — | — | CN | disclosed |
| WO-2022119914-A1 | METHODS OF INHIBITING RNA PROOFREADING AND THERAPEUTIC APPLICATIONS THEREOF | SCHMIER BRAD (US) | 2022-06-09 | — | — | WO | disclosed |
| US-11353448-B2 | Methods and compositions for quantifying metabolites and proteins from single cells | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2022-06-07 | — | — | US | disclosed |
| US-20220098282-A1 | PREVENTION OF PROTEIN DISULFIDE BOND REDUCTION | MEDIMMUNE LLC | 2022-03-31 | — | — | US | disclosed |
| EP-3386484-B1 | COMPOSITIONS AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX INC (US) | 2022-03-30 | — | — | EP | disclosed |
| US-11285222-B2 | Compositions and methods for delivery of agents | MODERNATX, INC. (US) | 2022-03-29 | — | — | US | disclosed |
| US-20220031631-A1 | HIGH-PURITY PEG LIPIDS AND USES THEREOF | MODERNATX, INC. (US) | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250152518-A1 | PEG LIPIDS AND USES THEREOF | LIPA, LIPG, LIPC | RNASEL 1352/4885ADORA1 4705/4885DNPH1 1795/4885 |
| US-20220031631-A1 | HIGH-PURITY PEG LIPIDS AND USES THEREOF | LIPA, HDLBP, PLTP | RNASEL 1117/4885ADORA1 4639/4885DNPH1 2573/4885 |
| US-11285222-B2 | Compositions and methods for delivery of agents | HDLBP, APOB, TSG101 | RNASEL 478/4885ADORA1 2677/4885DNPH1 4676/4885 |
| US-20260034071-A1 | HIGH-PURITY PEG LIPIDS AND USES THEREOF | LNPEP, AUP1, PLTP | RNASEL 2073/4885ADORA1 2269/4885DNPH1 2887/4885 |
| US-20220265857-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | HDLBP, APOB, TSG101 | RNASEL 478/4885ADORA1 2677/4885DNPH1 4676/4885 |
| US-12151029-B2 | PEG lipids and uses thereof | LIPA, LIPG, LNPEP | RNASEL 1205/4885ADORA1 4735/4885DNPH1 1887/4885 |
| US-12383508-B2 | High-purity peg lipids and uses thereof | LIPA, HDLBP, PLTP | RNASEL 1117/4885ADORA1 4639/4885DNPH1 2573/4885 |
| US-20250320190-A1 | Novel Inhibitors of Leucine Carboxyl Methyltransferase-1 (LCMT-1) and Methods of Use Thereof | GNMT, BHMT, SHMT1 | RNASEL 3543/4885ADORA1 3630/4885DNPH1 3251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.